A Safety Study for Previously Treated Vatiquinone (PTC743) Participants With Inherited Mitochondrial Disease
| 対象疾患 | Inherited Mitochondrial Disease |
|---|---|
| 相 | 第3相 |
| スポンサー | PTC Therapeutics |
| ステータス | 完了 |
| 参加者数 | 101 名 |
| 介入（薬剤） | Vatiquinone |
| 開始日 | 2022年6月22日 |
| 完了日 | 2025年4月15日 |
| 結果公開日 | 2025年12月22日 |
概要
The primary objective of this study is to assess the safety of vatiquinone in participants with inherited mitochondrial disease who had prior exposure to vatiquinone in a PTC/BioElectron sponsored (previously Edison) clinical study or treatment plan. The study will continue until vatiquinone becomes commercially available or the program is terminated.
Number of Participants With Treatment-emergent Adverse Events (TEAEs)
| Vatiquinone | 91 Participants |
|---|
BENITIONS で見る ClinicalTrials.gov の原文を見る
同じ疾患の他の治験
- Safety and Efficacy of tPBM for Epileptiform Activity in Autism — Richard Frye
- Randomized, Double-Blind Study to Evaluate Efficacy and Safety of Cenobamate Adjunctive Th — SK Life Science, Inc.
- Sphenopalatine Ganglion Nerve Block vs. Elavil for Treatment of Transformed Migraines — Rutgers, The State University of New Jersey
- Pharmacokinetics Study of Oral 2-Deoxy-D-Glucose (2DG) in Subjects With a Confirmed Diagno — University of Virginia
- A Study of Soticlestat as an Add-on Therapy in Children and Adults With Dravet Syndrome or — Takeda
- Maintenance TMS in Treatment Resistant Depression — Austin Messner